Affiliations: [a] Department of Urology, Faculty of Medicine, Selcuk University, Konya, Turkey | [b] Department of Urology, Faculty of Medicine, Turgut Özal University, Ankara, Turkey
Abstract:
BACKGROUND: The aim of the current study is to evaluate NLR and PLR inflammation
markers in PCa and BPH. METHODS: Clinical and pathological data such as age, prostate volume, PSA,
NLR, and PLR levels of 201 patients were retrospectively reviewed. Pathological
sample results of these patients were categorized either as benign or
malign. The benign group consisted of chronic prostatitis and BPH and the
malign group of PCa. The PSA levels were divided into three categories as
PSA: 0-4 ng/ml, PSA: 4-10 ng/ml, and 10 ng/ml and above. RESULTS: In the benign category, the mean PLR values for PSA: 0-4 ng/ml is
131.8 ± 31.2, for PSA: 4-10 ng/ml 124.7 ± 83.9 and 10 ng/ml and above 124
± 53 in chronic prostatitis group and in the BPH group for PSA: 4-10 ng/ml
120.3 ± 45.1, for PSA: 4-10 ng/ml 126 ± 54.2, and 10 ng/ml and above
191.4 ± 176.1. In the malign category, the mean PLR values of PCa
patients is for PSA: 0-4 ng/ml 122.8 ± 43.8, for PSA: 4-10 ng/ml
123 ± 43.8, and above 10 ng/ml 179.1 ± 94. Related to the variables
of age, NLR, and mean prostate volume, there were no statistically
significant differences. Statistically significant differences were observed
in the mean PLR values only if the PSA level was 10 ng/ml and above (p:
0.044) in the BPH and PCa groups. The correlation of the PCa Gleason score
and PSA, NLR and PLR parameters in the malign category revealed no
statistically significant differences (P > 0.05). CONCLUSION: Effective malign and benign differentiation of prostate
pathologies based on noninvasive inflammation biomarkers such NLR and PLR
necessitate clinical studies with larger patient series.
Keywords: Benign prostatic hyperplasia, prostate cancer, platelet to lymphocyte ratio
